TVRD
Tvardi Therapeutics, Inc. NASDAQ Listed Apr 16, 2025$1.77
+0.57%
vs $1.76
Mkt Cap $13.8M
52w Low $1.50
0.7% of range
52w High $42.98
50d MA $2.59
200d MA $3.56
P/E (TTM)
-0.6x
EV/EBITDA
—
P/B
0.6x
Debt/Equity
0.0x
ROE
-87.0%
P/FCF
-0.6x
RSI (14)
6.20
ATR (14)
$0.19
Beta
0.15
50d MA
$2.59
200d MA
$3.56
Avg Volume
4.6M
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
2450 Holcombe Blvd, Suite X · Sugar Land, TX 77021 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | AMC | -0.55 | -0.78 | -41.8% | 3.18 | -1.6% | -5.7% | +0.7% | -1.3% | -4.4% | +7.0% | — |
| Nov 13, 2025 | AMC | -0.83 | -0.59 | +28.9% | 4.11 | -0.7% | -1.9% | +0.0% | +2.2% | -4.6% | -2.8% | — |
| Aug 14, 2025 | AMC | -0.51 | -1.00 | -96.1% | 23.79 | +3.4% | +0.9% | +3.1% | -0.3% | +9.0% | -0.9% | — |
| May 13, 2025 | AMC | -0.58 | -3.22 | -450.4% | 26.54 | -4.4% | -0.7% | +1.6% | -5.8% | +3.8% | +5.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jul 8 | Raymond James | Upgrade | Mkt Perform → Outperform | $10 | $3.10 | $3.23 | +4.2% | +61.3% | -24.0% | -13.7% | +0.9% | -6.3% |
| Jun 8 | H.C. Wainwright | Initiates | Buy | $9 | $2.89 | $3.05 | +5.5% | -1.4% | -2.5% | -2.9% | +0.4% | -2.6% |
| Apr 20 | Barclays | Downgrade | Equal Weight → Underweight | — | $3.39 | $3.38 | -0.3% | -5.0% | -1.9% | +2.2% | -6.8% | +3.0% |
| Apr 1 | Barclays | Maintains | Equal Weight → Equal Weight | — | $3.18 | $3.13 | -1.6% | -5.7% | +0.7% | -1.3% | -4.4% | +7.0% |
| Apr 1 | BTIG | Maintains | Buy → Buy | — | $3.18 | $3.13 | -1.6% | -5.7% | +0.7% | -1.3% | -4.4% | +7.0% |
| Apr 1 | Piper Sandler | Maintains | Neutral → Neutral | — | $3.18 | $3.13 | -1.6% | -5.7% | +0.7% | -1.3% | -4.4% | +7.0% |
| Oct 14 | Raymond James | Downgrade | Outperform → Market Perform | — | $6.69 | $6.65 | -0.6% | +4.6% | -5.1% | -2.4% | +1.5% | -6.2% |
| Oct 13 | BTIG | Maintains | Buy → Buy | — | $41.60 | $6.20 | -85.1% | -83.9% | +4.6% | -5.1% | -2.4% | +1.5% |
No insider trades available.
8-K · 7.01
! Medium
Tvardi Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jul 30
8-K · 7.01
! Medium
Tvardi Therapeutics, Inc. -- 8-K 7.01: Regulation FD Disclosure
Jul 7
8-K · 2.02
!! High
Tvardi Therapeutics, Inc. -- 8-K 2.02: Earnings Results
Tvardi Therapeutics reported Q1 2026 financial results via press release, with the 8-K filing providing official documentation of the company's operational performance and financial condition for investor disclosure.
May 8
8-K
Unknown — 8-K Filing
Tvardi's clinical-stage pipeline targeting STAT3 for inflammatory/proliferative diseases may advance treatment options, but investors should demand clarity on cash runway, trial timelines, and regulatory milestones to assess viability.
Mar 31
8-K · 8.01
!! High
Tvardi Therapeutics, Inc. -- 8-K 8.01: Material Event / Announcement
Tvardi Therapeutics announced its deadline for stockholder proposals to be included in the 2026 Annual Meeting proxy materials, requiring submission well in advance of proxy printing.
Mar 6
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Vanguard Capital Management Llc | 344,708 | $1M | New | Mar 2026 |
| 2 | Morgan Stanley | 168,932 | $726K | Added | Dec 2025 |
| 3 | American Financial Group Inc | 223,659 | $711K | — | Mar 2026 |
| 4 | Renaissance Technologies Llc | 92,100 | $293K | Reduced | Mar 2026 |
| 5 | Jane Street Group, Llc | 47,444 | $204K | New | Dec 2025 |
| 6 | Ubs Group Ag | 50,454 | $160K | Added | Mar 2026 |
| 7 | Northern Trust Corp | 49,081 | $156K | Added | Mar 2026 |
| 8 | Aqr Capital Management Llc | 42,192 | $134K | New | Mar 2026 |
| 9 | Great Lakes Advisors, Llc | 36,236 | $115K | New | Mar 2026 |
| 10 | Vanguard Portfolio Management Llc | 33,833 | $108K | New | Mar 2026 |
| 11 | Russell Investments Group, Ltd. | 23,307 | $74K | Added | Mar 2026 |
| 12 | Farallon Capital Management Llc | 21,438 | $68K | New | Mar 2026 |
| 13 | Bank Of New York Mellon Corp | 17,405 | $55K | Reduced | Mar 2026 |
| 14 | Fmr Llc | 5,278 | $17K | Reduced | Mar 2026 |
| 15 | Jpmorgan Chase & Co | 2,565 | $8K | Added | Mar 2026 |
| 16 | Wells Fargo & Company/mn | 2,266 | $7K | New | Mar 2026 |
| 17 | Cwm, Llc | 1,706 | $5K | Added | Mar 2026 |
| 18 | Bnp Paribas Financial Markets | 1,426 | $5K | Added | Mar 2026 |
| 19 | Barclays Plc | 946 | $3K | Reduced | Mar 2026 |
| 20 | Mcilrath & Eck, Llc | 20 | $64 | New | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$13.8M
Enterprise Value
-$17.0M
P/E (TTM)
-0.57x
Forward P/E
—
PEG Ratio
0.02x
P/B
0.63x
P/S
—
P/FCF
-0.59x
EV/EBITDA
—
Shares Out
7.8M
Financials (TTM)
Revenue
$0
Net Income
-$15.4M
EBITDA
-$15.3M
Free Cash Flow
-$23.5M
Op Cash Flow
-$23.5M
EPS Basic
$-2.46
EPS Diluted
$-3.10
EPS Forward
$-2.31
Gross Margin
—
Op Margin
—
Net Margin
—
Balance Sheet
Total Assets
$32.1M
Total Liab.
$11.1M
Total Equity
$20.9M
Cash
$30.8M
LT Debt
$0
Book Value/Sh
$2.82
Debt/Equity
0.01x
Current Ratio
2.86
Quick Ratio
2.86
Returns & Growth
ROE
-87.0%
ROA
-56.8%
ROIC
-126.5%
Rev Growth YoY
-100.0%
EPS Growth YoY
+94.7%
Price Returns
2W
-30.7%
1M
-46.3%
3M
-55.6%
6M
-53.4%
12M
-92.7%
Technicals
52W High
$42.98
52W Low
$1.50
50d MA
$2.59
200d MA
$3.56
RSI (14)
6.20
ATR (14)
$0.19
Beta
0.15
Avg Volume
4.6M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$3.00
High
$3.00
Low
$3.00
Median
$3.00
Data updated apr 27, 2026 6:08am
· Source: financialmodelingprep.com